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Abstract
Background: In the United States, about 70% of 2.9-3.7 million people with hepatitis C (HCV) are unaware of their
infection. Although universal screening might be a cost-effective way to identify infections, prevent morbidity, and
reduce transmission, few efforts have been made to determine patient opinions about new approaches to
screening.
Methods: We surveyed 200 patients in August 2010 at five outpatient clinics of a major public urban medical
center in Seattle, WA, with an 85.8% response rate.
Results: The sample was 55.3% women, median 47 years of age, and 56.3% white and 32.7% African or African-
American; 9.5% and 2.5% reported testing positive for HCV and HIV, respectively. The vast majority of patients
supported universal screening for HCV. When presented with three options for screening, 48% preferred universal
testing without being informed that they were being tested or provided with negative results, 37% preferred
testing with the chance to “opt-out” of being tested and without being provided with negative results, and 15%
preferred testing based on clinician judgment. Results were similar for HIV screening.
Conclusions: Patients support universal screening for HCV, even if that screening involves testing without prior
consent or the routine provision of negative test results. Current screening guidelines and procedures should be
reconsidered in light of patient priorities.
Background
Hepatitis C infection (HCV) is a neglected disease.
Approximately 1.6% of the U.S. population (2.9 to 3.7
million people) is infected with HCV[1], 20-30% will
progress to cirrhosis, and 49-75% are unaware of their
infection[2]. HCV is the most common underlying cause
of liver failure among persons undergoing liver trans-
plant in the U.S. and kills approximately 14,000 Ameri-
cans annually[2]. The number of new cases of cirrhosis
from HCV is predicted to increase by over 30% as of
2020 and subsequent liver decompensation, hepatocellu-
lar carcinoma, and death will continue to increase into
the 2030s[3]. Current therapy for HCV is curative for
a b o u t5 0 %o ft r e a t e dp a t i e n t sa n dc o u l dd e c r e a s et h e s e
complications by 16-42% if implemented broadly[3].
Soon to be available protease inhibitor regimens are
expected to cure over 70%[4,5] and thus could have a
more dramatic impact. Yet despite the scale of the pro-
blem and the availability of increasingly effective treat-
ment, relatively little has been done to identify persons
with HCV and ensure their treatment.
National guidelines recommend that testing for HCV
be limited to persons with identified risk factors, such as
injection drug use, a blood transfusion prior to 1992, or
elevated liver function tests[6]. Although these recom-
mendations are based on epidemiologic data and 1998
Centers for Disease Control and Prevention (CDC)
guidelines[7], barriers to risk-based screening have
resulted in inadequate detection of HCV. Most impor-
tantly, patients with a remote history of injection drug
use, the primary risk factor for HCV, are often reluctant
to admit that behavior to a clinician; only 21% of
respondents with HCV reported IDU in the National
Health and Nutrition Examination Survey IV [8]. In all
but the most complex guidelines, risk factor-based
screening also fails to account for suspected transmis-
sion routes, such as remote iatrogenic transmission,
intranasal drug use[9] or even a fist fight[10]. Overall,
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plex for routine clinical care.
Due to barriers to risk-factor based HIV screening,
including the ability to reliably assess risk in the clinical
setting, the CDC in 2006 recommended routine “opt-
out” general population screening for HIV[11]. The
requirement for separate consent to test for HIV in
many states and inadequate time for counseling[12] con-
tinue to impede testing, with attendant reductions in the
proportion of patients screened for HIV[13]. Such bar-
riers may still be too onerous to ensure detection of the
estimated 21% of HIV-infected Americans who are una-
ware of their infection[14]. Likewise, another set of
complex screening criteria or a clinician-driven
approach to HCV screening may fail us in the effort to
diagnose and care for the two to three million U.S. resi-
dents unaware of their HCV infection.
The debate surrounding patient consent for diagnostic
testing or screening highlights the tension within the
healthcare system between a desire to respect patient
autonomy, contain costs, and maximize detection of
treatable medical conditions. Unfortunately, patients are
often the missing voice in this debate, and little is
known about the relative importance patients place on
being informed, consented, and tested. In considering a
future HCV screening intervention, we evaluated patient
opinion at a large public, urban hospital.
Methods
We conducted an anonymous, self-administered, cross-
sectional survey of outpatients at five clinics at Harbor-
view Medical Center, a public urban hospital and regio-
nal trauma center in Seattle, WA, to define the
importance that patients place on testing for HCV, com-
pared to HIV and diabetes mellitus. We included HIV
as testing requires special consent procedures, thus uni-
versal screening for HIV might raise additional concerns
relative to HCV. We included diabetes because a man-
ner of universal screening is already de facto present in
every chemistry panel with a glucose result, but consent
is not consistently obtained and normal results may be
inconsistently discussed with patients (even abnormal
results are only discussed with patients 66-88% of the
time[15]). This study was approved by the Human Sub-
jects Division of the University of Washington.
The instrument was piloted with five patients, met a
Flesh-Kincaid fifth-grade reading level, and was in Eng-
lish, a language accessible to 90% of this hospital’s
patients (personal communication, Harborview Inter-
preter Services, 2 July 2010). We collected patient
demographics and expectations as to physician commu-
nication regarding laboratory testing.
The remaining sections addressed HCV, HIV, and dia-
betes. Each section was preceded by a brief description
of the disease and a statement that some people do not
learn about their condition until they are sick. Initial
questions in each section asked subjects’ disease status
and risk factors, followed by a series of questions about
aspects of universal screening detailed in the accompa-
nying tables. All questions were asked of HCV, but to
ensure brevity only a subset of questions were included
in sections on HIV and diabetes. The primary outcome
variable, asked of HCV and HIV, allowed respondents
to select one of three screening options: (1) universal
screening of all blood samples without patient knowl-
edge of the test and without receiving negative results,
(2) universal screening without receiving negative results
but with a chance to refuse testing, or (3) screening
based on clinician judgment. Comments were solicited
at the end of the survey.
Forty surveys were collected from each of five clinics
(General Medicine, Family Medicine, Womens’, General
Surgery, and Orthopedics), selected to represent the
diverse nature of outpatient care, including primary care
serving a largely inner-city population and surgical care
serving five northwest states. Researchers sequentially
approached all patients in the waiting room after they
had checked into the clinic and completed registration
paperwork. Eligible subjects were more than 15 years of
age, able to communicate in English, and had not pre-
viously completed the survey. Interested subjects were
provided an “information sheet” in lieu of signed consent
and, if they still wanted to participate, a survey and pen-
cil. Subjects completed the survey in the waiting area or a
clinic room and received $5 compensation when they
returned the completed survey to the researcher. All data
collection activities were completed in August 2010.
Data were analyzed with STATA 11.1, utilizing
descriptive statistics, Pearson’s Chi-square, and McNe-
mar’s test of matched pairs. To evaluate for any associa-
tions with the primary outcome of preferred screening
method, we collapsed the two options for universal
screening and compared those respondents to those
who preferred screening by clinician judgment. Missing
values were excluded. We coded optional comments
based on identified themes.
Results
A total of 233 patients were eligible and 200 (86%) com-
pleted the survey. Data were not collected for non-
responders. Over half (55%) of respondents were women
and the median age was 47 years (range 18-82). One-
hundred twelve (56%) respondents were white, 65 (33%)
were African or African-American, and 16 (8%) were
Hispanic or Latino. Demographics compared to the
2010 census by clinic are presented in Table 1.
Twenty-three (12%) respondents reported ever inject-
ing drugs, 39 (20%) reported having had a blood
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having sex with another man. A majority of participants
reported previous testing for HIV, HCV and diabetes
(see Table 2). Ninety-seven (50%) respondents reported
that their doctor always told them about all of the tests
being run on their blood and another 46 (24%) reported
that happened most of the time; 174 (87%) reported
that it was very important for them to know what tests
were being done on their blood. The vast majority
wanted to know if they had HCV, HIV, or diabetes.
Most also indicated that the hospital should automati-
cally test all patients for each condition, although analy-
sis of matched pairs illustrated greater support for
automatically testing all patients for HCV (p = 0.01) or
HIV (p = 0.03) compared to diabetes.
Although almost two-thirds of respondents indicated
that it would not be acceptable to test them for HCV
without first telling them about the test, 75% indicated
that they would prefer to be tested without knowing
about it than not to be tested at all. More than three-
quarters indicated that it would not be acceptable to be
tested for HCV without receiving negative results. How-
ever, when presented with three screening options, the
largest proportion favored universal screening without
knowing about the test or receiving negative results and
the smallest proportion favored relying on clinician
judgment. Three-quarters of respondents indicated that
they would accept being contacted with a positive result
by a public health department representative.
There were no significant associations between demo-
graphic characteristics, risk factors, testing history or
disease status and the acceptability of universal screen-
ing for HCV (see Table 3). Respondents who wanted to
know if they were infected with HCV were more likely
to support universal screening (p < 0.01). Acceptance of
universal screening for HCV was also associated with
agreement that the hospital should test all patients for
HCV, and that testing should be automatic. Results of
the analysis applied to HIV testing were the same as for
HCV testing, including the absence of associations with
demographics, risk factors, testing history or disease sta-
tus, and positive associations with desire to know
disease status and belief that testing should be auto-
matic and for all patients (data not shown).
Themes identified on qualitative review of 85 optional
comments included: testing would be good for indivi-
dual patient health (29 comments), testing would be
good for public health (20 comments), all patients
should have to be tested to receive care (6 comments),
patients should be told they are being tested (7 com-
ments), testing should be done through patients’ doctors
(1 comment), cost of testing should be considered (3
comments), testing should be free (1 comment), enjoyed
survey (19 comments), unrelated (3 comments). Two
respondents suggested that universal screening should
be limited to communicable diseases.
Discussion
We found that most patients seeking outpatient care at
an urban public hospital supported universal screening
for HCV, as well as HIV and diabetes. While most pre-
ferred to know that they were being tested and to
receive negative results, our findings suggest that
patients believed that ensuring universal testing for
HCV was more important than either soliciting patient
consent for the test or providing negative test results.
Notably, our results also suggest that patients were
more supportive of universal screening for HCV and
HIV than they were for diabetes, even though diabetes
was the most common of the three medical conditions
and diabetes screening is not governed by the sorts of
regulations that limit HIV testing. Optional comments
suggested that some patients might distinguish a greater
public health value in patient awareness of infectious
compared to non-communicable diseases.
We do not believe that these findings should immedi-
ately prompt health care providers or organizations to
abandon efforts to inform patients and seek consent for
testing. However, efforts to broadly screen populations
for communicable diseases have met formidable barriers.
Although the first studies documenting a high preva-
lence of undiagnosed HIV in some urban emergency
departments were published almost 20 years ago[16],
very few such departments have instituted expanded
Table 1 Demographic characteristics of survey respondents (N = 200) and 2010 clinic census (N = 18,117)
General Medicine Family Medicine Womens’ General Surgery Orthopedics
Survey | Census Survey | Census Survey | Census Survey | Census Survey | Census
Female 58% | 45% 45% | 59% 100%|100% 33% | 35% 41% | 36%
Median age (years) 40-49 | 50-59 40-49 | 40-49 20-29 | 30-39 40-49 | 40-49 40-49 | 40-49
Non-Hispanic White 53% | 47% 36% | 28% 23% | 31% 53% | 61% 65% | 76%
Non-Hispanic African-American 24% | 33% 48% | 44% 53% | 43% 20% | 20% 12% | 12%
Hispanic/Latino 5% | 7% 8% | 10% 8% | 15% 13% | 13% 8% | 5%
*Race/ethnicity was collected as two variables in the survey and one variable in the census (including Hispanic/Latino ethnicity), thus proportions do not match text
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required hiring new staff, a cost that often makes the
programs unsustainable. It remains uncertain whether
medical institutions in the U.S. can widely screen
patients for communicable diseases if such screening
requires procedures that are not in place for other
chronic conditions. While electronic medical record
reminders have led to modest improvements in
Table 2 Opinions and preferences for screening for hepatitis C virus (HCV) compared to HIV and diabetes (N = 200)
HCV HIV Diabetes
No (%) No (%) No (%)
Have you been tested for ___?
Yes 102 (51.0) 135 (68.2) 125 (63.5)
No/Don’t Know 98 (49.0) 63 (31.8) 72 (36.5)
Tested positive for ___
Yes 19 (18.8) 5 (3.7) 32 (25.6)
No/Don’t Know 82 (81.2) 130 (96.3) 93 (74.4)
Would you want to know if you had ___?
Yes 172 (86.9) 186 (94.9) 186 (95.4)
No/Don’t Know 26 (13.1) 10 (5.1) 9 (4.6)
Should the hospital test ALL its patients for ___?
Yes 149 (76.0) 142 (73.2) 131 (68.3)
No 16 (8.2) 23 (11.9) 37 (19.3)
Don’t Know 31 (15.8) 29 (14.9) 24 (12.5)
One way to test everyone is to test all blood for ___ automatically. Would you be OK being tested this way?
Yes 168 (86.2) 159 (80.7) 145 (75.9)
No 17 (8.7) 23 (11.7) 30 (15.7)
Don’t Know 10 (5.1) 15 (7.6) 16 (8.4)
Preferred screening approach and potential concerns
Which way is best to test for ___?
Test all blood for ___. You might not know the test is being done. People who test negative would not be
told the result.
91 (48.4) 91 (50.3) n/a
Test all blood for ___. You would have a chance to ask NOT to be tested. People who test negative would
not be told the result.
69 (36.7) 64 (35.4) n/a
Let each doctor decide who to test. 28 (14.9) 26 (14.4) n/a
Would it be OK to test you for ___ automatically without talking to you about the test first?
Yes 67 (34.7) 69 (35.4) n/a
No 120 (62.2) 112 (57.4) n/a
Don’t Know 6 (3.1) 14 (7.2) n/a
If we found that you did NOT have ___, would it be okay if you did NOT get the results?
Yes 43 (21.7) n/a 77 (40.5)
No 148 (74.8) n/a 108 (56.8)
Don’t Know 7 (3.5) n/a 5 (2.6)
Do you think it’s better to be tested for ___ without knowing about it or not to be tested at all?
Be tested without knowing 134 (75.3) n/a n/a
Not be tested at all 44 (24.7) n/a n/a
If we found out you DID have ___, would it be okay if someone from the health department told you the
result? This would keep the result out of your medical record.
Yes 143 (73.3) n/a n/a
No 28 (14.4) n/a n/a
Don’t Know 24 (12.3)
n/a = question was not asked for condition
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or population-based public health interventions, possibly
involving pooled ribonucleic acid screening,[19] may be
necessary to address the burden of undiagnosed HCV.
The results of this survey suggest that many patients
would forego certain standards for consent to ensure
timely diagnosis of HCV.
There are several limitations to this study. First and
foremost, we are uncertain of the generalizability of our
findings. We found no differences in screening prefer-
ence between those seeking primary medical care and
those seeking care for orthopedic and other surgical dis-
ease at this regional level 1 trauma center, and no differ-
ences based on HCV or HIV risk factors, testing history,
or serostatus. Nonetheless, social and cultural differ-
ences may produce discordant results at other sites. Sec-
ond, we did not confirm the self-reported histories of
testing or disease status. To ensure brevity of the instru-
ment, not all questions were asked of all conditions, lim-
iting our ability to compare opinions across conditions.
Finally, as a primarily quantitative instrument, we may
have missed issues that could emerge in qualitative
research, a concern we attempted to address through
piloting the instrument and evaluating comments.
Conclusions
In summary, our findings demonstrate that patients sup-
port universal testing for HCV, as well as HIV, that an
“opt-out” program would be preferred if feasible, but
that patients appear to place a higher priority on being
tested than they do on the process of informed consent
or the receipt of negative results. These findings should
inform the priorities of clinicians, public health officials,
and clinical risk managers.
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Table 3 Associations with hepatitis C virus screening
preference (N = 188)
Universal
Screening
No (row%)
Clinician
Judgment
No (row%)
Clinic
General Medicine 32(82.1) 7(17.9)
Family Medicine 28(77.8) 8(22.2)
Womens’ 36(90.0) 4(10.0)
General Surgery 30(85.7) 5(14.3)
Orthopedics 34(89.5) 4(10.5)
Gender
Male 70(84.3) 13(15.7)
Female 89(85.6) 15(14.4)
Age (quartiles)
16-32 44(89.8) 5(10.2)
33-47 49(86.0) 8(14.0)
48-56 31(79.5) 8(20.5)
57-82 35(83.3) 7(16.7)
Race/ethnicity
White 87(83.7) 17(16.4)
African/African-American 52(85.3) 9(14.8)
Asian 8(88.9) 1(11.1)
Native Am/Alaskan Native 7(100.0) 0(0.0)
Hawaiian/Pacific Islander and Other 4(100.0) 0(0.0)
Hispanic/Latino
No 143(84.1) 27(15.9)
Yes 14(93.3) 1(6.7)
How often does your doctor tell you
ALL tests being done?
Always/Most of the time 113(83.1) 23(16.9)
Sometimes/Never 44(89.8) 5(10.2)
Importance of knowing ALL tests being
done
Very 136(84.0) 26(16.0)
Somewhat/Not 24(92.3) 2(7.7)
Ever injected drugs not prescribed by a
doctor
Yes 17(81.0) 4(19.0)
No 142(85.5) 24(14.5)
History of blood transfusion
Yes 36(92.3) 3(7.7)
No/Don’t Know 124(83.2) 25(16.8)
Sexual orientation
Heterosexual/straight 137(84.6) 25(15.4)
Gay/lesbian/queer 7(100.0) 0(0.0)
Bisexual 14(87.5) 2(7.4)
Have you been tested for HCV?
Yes 82(87.2) 12(12.8)
No/Don’t Know 78(83.0) 16(17.0)
Table 3 Associations with hepatitis C virus screening pre-
ference (N = 188) (Continued)
Tested positive
Yes 16(88.9) 2(11.1)
No/Don’t Know 66(88.0) 9(12.0)
Would you want to know if you had
HCV?*
Yes 145(88.4) 19(11.6)
No/Don’t Know 15(65.2) 8(34.8)
*p < 0.01
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